Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 92% Improvement Relative Risk ICU admission -22% Days alive and discharge.. -8% Sivapalan et al. NCT04322396 HCQ RCT LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Double-blind RCT 117 patients in Denmark Lower mortality with HCQ (not stat. sig., p=0.32) Sivapalan et al., European Respiratory J., doi:10.1183/13993003.00752-2021 Favors HCQ Favors control
Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19–a randomised double-blinded placebo-controlled trial
Sivapalan et al., European Respiratory Journal, doi:10.1183/13993003.00752-2021, NCT04322396 (history)
Sivapalan et al., Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19–a randomised.., European Respiratory Journal, doi:10.1183/13993003.00752-2021, NCT04322396
Jun 2021   Source   PDF  
  All Studies   Meta
Early terminated late stage (8 days from onset, 59% on oxygen) RCT not showing statistically significant differences. NCT04322396 (history) ProPAC-COVID. NNF20SA0062834.
risk of death, 92.0% lower, RR 0.08, p = 0.32, treatment 1 of 61 (1.6%), control 2 of 56 (3.6%), adjusted per study.
risk of ICU admission, 22.4% higher, RR 1.22, p = 1.00, treatment 4 of 61 (6.6%), control 3 of 56 (5.4%).
relative days alive and discharged from hospital within 14 days (inverse), 8.4% worse, RR 1.08, p = 0.36, treatment 61, control 56, adjusted per study.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Sivapalan et al., 3 Jun 2021, Double Blind Randomized Controlled Trial, Denmark, peer-reviewed, 32 authors, average treatment delay 8.0 days, trial NCT04322396 (history).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Early View Original article research Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19–a randomised double-blinded placebo-controlled trial Pradeesh Sivapalan, Charlotte Suppli Ulrik, Therese Sophie Lapperre, Rasmus Dahlin Bojesen, Josefin Eklöf, Andrea Browatzki, Jon Torgny Wilcke, Vibeke Gottlieb, Kjell Erik Julius Håkansson, Casper Tidemandsen, Oliver Tupper, Howraman Meteran, Christina Bergsøe, Eva Brøndum, Uffe Bodtger, Daniel Bech Rasmussen, Sidse Graff Jensen, Lars Pedersen, Alexander Jordan, Helene Priemé, Christian Søborg, Ida E. Steffensen, Dorthe Høgsberg, Tobias Wirenfeldt Klausen, Martin Steen Frydland, Peter Lange, Asger Sverrild, Muhzda Ghanizada, Filip Krag Knop, Tor Biering-Sørensen, Jens D. Lundgren, Jens-Ulrik Stæhr Jensen, Please cite this article as: Sivapalan P, Suppli Ulrik C, Sophie Lapperre T, et al. Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19–a randomised double-blinded placebo-controlled trial. Eur Respir J 2021; in press ( This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Copyright ©The authors 2021. This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contactt Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19 - a randomised doubleblinded placebo-controlled trial by the ProPAC-COVID study group* *A complete list of members in the Proactive Protection with Azithromycin and hydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID) Study Group is provided in Supplementary Appendix 3. The ProPAC-COVID study is an initiative by the independent research network COP:TRIN ( The members of the writing group (Pradeesh Sivapalan, MD, PhD; Charlotte Suppli Ulrik, MD, DMSc; Therese Sophie Lapperre, MD, PhD; Rasmus Dahlin Bojesen, MD, PhD; Josefin Eklöf, MD, PhD; Andrea Browatzki, MD; Jon Torgny Wilcke, MD, PhD; Vibeke Gottlieb, MD, PhD; Kjell Erik Julius Håkansson, MD; Casper Tidemandsen, MD; Oliver Tupper, MD, PhD; Howraman Meteran, MD; Christina Bergsøe, BSc; Eva Brøndum, RN; Uffe Bodtger, MD, PhD; Daniel Bech Rasmussen, MD, PhD; Sidse Graff Jensen, MD, PhD; Lars Pedersen, MD, PhD; Alexander Jordan, BSc; Helene Priemé, MD, PhD; Christian Søborg, MD, PhD; Ida E. Steffensen, MD, PhD; Dorthe Høgsberg, RN; Tobias Wirenfeldt Klausen, MSc, PhD; Martin Steen Frydland, MD, PhD; Peter Lange, MD, DMSc; Asger Sverrild, MD, PhD; Muhzda Ghanizada, MD; Filip Krag Knop, MD, PhD; Tor Biering-Sørensen, MD, PhD, MPH; Jens D. Lundgren, MD, DMSc and Jens-Ulrik Stæhr Jensen, MD, PhD [protocol chair, Copenhagen COP:TRIN lead]) of the ProPAC-COVID Study Group assume responsibility for the overall content and integrity of this article. The affiliations of the members of the writing group are listed in the Appendix. Corresponding author: Professor Jens-Ulrik Stæhr Jensen, COP:TRIN/Department of Medicine, Herlev-Gentofte Hospital, University of Copenhagen, Denmark. Gentofte hospitalsvej 1, 2900 Hellerup. Phone: +45 2893 8168;..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop